Estudo mostra atividade reduzida de anticorpos neutralizantes, induzida pela vacina da Pfizer–BioNTech, contra as variantes de preocupação do SARS-CoV-2 B.1.617.2 (Delta) e B.1.351 (Beta).

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2  and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet

Comentário: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute

Comentário no Twitter (fio – clique para saber mais)

“Immune escape” in #DeltaVariant. That’s the latest finding – that #B16172 is as bad for antibody neutralization as the Beta variant #B1351 from South Africa 🇿🇦. 1st dose alone very small effect— 2 doses needed, but weakest against Delta. Let’s walk through evidence 🧵 #COVID19 https://t.co/GurgkNVgiY pic.twitter.com/o0s9WIudCW

— Eric Feigl-Ding (@DrEricDing) June 5, 2021